In recent years, the pharmaceutical industry has set off a wave of departures
.
Since 2021, more than 60 European and American pharmaceutical and biological companies have announced layoffs, including many familiar large multinational pharmaceutical companies such as Merck, Glaxo, Sanofi, Novartis, etc.
, as well as some emerging strong pharmaceutical industry companies, such as Acadia Healthcare, Brookdale, ALERIS, etc
.
Among them, Novartis announced the new organizational structure in the first half of the year, and plans to lay off thousands of employees
worldwide.
It said it would reduce more than 100 jobs
at its plants in Rot cruz and Basel in Switzerland.
Recently, Novartis said it plans to cut as many as 8,000 jobs nationwide, including 1,400 in Switzerland, which is reported to be part of a previously disclosed restructuring plan aimed at saving about $1 billion in costs
.
In addition to the frequent layoffs of multinational pharmaceutical companies, domestic companies are also difficult to escape this luck, according to statistics show that in the past year, 116 pharmaceutical companies have carried out different degrees of layoffs, the total number of layoffs is nearly 40,000
.
Among them, hengrui pharmaceutical, Yuheng pharmaceutical, East Sunshine and other large local pharmaceutical companies lay off thousands of people
.
According to the annual report of Hengrui Pharmaceutical, during the year, Hengrui Pharmaceutical promoted sales reform and optimized the sales staff from 17138 at the beginning of the year to 13208.
Calculated in this way, only the sales staff, Hengrui Pharmaceutical optimized 3930 people
a year.
At present, from the perspective of the motives of major pharmaceutical companies for layoffs, the main reason is due to the changeable pharmaceutical market environment and the continuous deepening of medical correction
.
Especially in recent years, with the normalization of collection and procurement, the continuous advancement of medical insurance control fees, and the decline in drug prices have become a trend, forcing enterprises to accelerate innovation and upgrading, and affected by this, many companies have begun to frequently lay off employees
in order to cut costs, optimize structure, and focus on advantageous businesses.
In this regard, the industry believes that layoffs are to increase the profits of pharmaceutical companies, but they are not necessary
.
The growth of the profit of pharmaceutical companies still needs to be carried out
by increasing sales revenue, increasing gross profit, reducing costs, and improving net profits.
At present, it can be clearly seen that many enterprises will also recruit some new personnel who can bring higher benefits to enterprises while reducing personnel
.
For example, many enterprises are actively recruiting R&D positions and pharmaceutical representative positions
.
According to industry statistics, as of April 6, the number of employees in six CXO head companies has increased, with a cumulative increase of 18,000 people
.
Among them, WuXi AppTec added 8501 employees, of which 6899 were R&D personnel, and BeiGene added 2822 R&D personnel in 2021, accounting for 96%
of the annual R&D personnel.
In addition, in 2021, the number of R&D people of Hengrui Pharmaceutical also increased by 16%.
In addition, Pfizer announced its digital layout and decided to cut hundreds of sales positions in the United States and India, and said it would increase its digital-related jobs
by about half.
It can be seen from the above that for pharmaceutical companies, compared with layoffs, the future will be more frequent in the transformation and innovation of marketing strategies, and at the same time, the demand for professionals who meet the development of enterprises will become more and more vigorous
.
